|
GB201916808D0
|
|
Pharmaceutical delivery device
|
|
WO2020100080A1
|
|
Compounds, compositions and methods for treating sepsis
|
|
WO2020084530A1
|
|
Mucoadhesive pharmaceutical compositions of corticosteroids
|
|
TW202027780A
|
|
Compositions and methods for controlled ovarian stimulation
|
|
WO2020074734A1
|
|
Method for manufacturing a solid formulation for oral administration, associated facility and solid formulation
|
|
WO2020018668A1
|
|
Combination therapy comprising microbiota restoration therapy (mrt) compositions
|
|
EP3806823A1
|
|
Terlipressin compositions and uses thereof
|
|
WO2019213595A1
|
|
Microbiota restoration therapy (mrt) compositions and methods of manufacture
|
|
BR112020021852A2
|
|
improved pharmaceutical formulations
|
|
TW201945024A
|
|
Composition for controlled ovarian stimulation
|
|
EP3784210A1
|
|
Topical pharmaceutical composition for treatment of anal fissures and hemorrhoids
|
|
WO2019136053A1
|
|
Oral liquid pharmaceutical compositions of aminosalicylates
|
|
WO2019125166A2
|
|
Hyaluronic acid formulations
|
|
WO2019110688A1
|
|
A composition comprising degarelix for use in the treatment of breast cancer
|
|
FR3087659A1
|
|
MINIATURIZED DEVICE FOR AUTOMATED MANUFACTURING OF PHARMACEUTICAL COMPOSITIONS, AND ASSOCIATED PROCESS
|
|
EP3675894A1
|
|
Composition for controlled ovarian stimulation
|
|
AU2018312956A1
|
|
Method of manufacturing a pharmaceutical composition
|
|
US2019135859A1
|
|
Method of manufacturing a pharmaceutical composition
|
|
WO2018193423A1
|
|
Oral pharmaceutical compositions of corticosteroids
|
|
GB201803494D0
|
|
Treatment regime
|
